Physician profile
Stefan K Barta
NPI 1336384130
$64,126.66
in general payments reported to CMS, 2019-2025
12 companies · $6,342 in 2025
The $6,342 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,480 · 2020: $7,751 · 2021: $6,515 · 2022: $21K · 2023: $10K · 2024: $8,269 · 2025: $6,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,915 · Food and Beverage: $918 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,914.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,915.18 |
| Food and Beverage | $917.57 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $28,313.50 | 2021-2025 | Beleodaq |
| Janssen Research & Development, LLC | $16,652.50 | 2019-2025 | |
| Kyowa Kirin, INC. | $7,654.99 | 2019-2025 | Poteligeo |
| Seagen INC. | $5,522.71 | 2020-2023 | |
| Daiichi Sankyo INC. | $2,446.22 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,779.00 | 2024 | |
| Pfizer INC. | $1,562.98 | 2019-2024 | |
| Genmab U.S., INC. | $136.86 | 2023 | Epkinly |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Kite Pharma, INC. | $14.65 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Barta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.